This product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from A-549 human lung adenocarcinoma cells, engineered to disrupt the ARAP1 gene and generate a mixed pool of knockout cells. The polyclonal nature of this population reflects the inherent heterogeneity of CRISPR-mediated gene disruption across the cell pool, providing a robust loss-of-function model for investigating ARAP1-dependent signaling processes without the clonal selection artifacts that can arise in single-cell-derived lines.
The A-549 cell line is a well-characterized human lung adenocarcinoma epithelial model originally established from a 58-year-old Caucasian male. These cells maintain features of alveolar basal epithelial cells and are widely employed in cancer research as a representative system for non-small cell lung cancer (NSCLC). They express wild-type EGFR and other key signaling molecules, making them particularly suited for studies of receptor tyrosine kinase trafficking, cytoskeletal dynamics, and oncogenic signaling pathways relevant to lung adenocarcinoma biology.
ARAP1 functions as a dual GTPase-activating protein (GAP) for both Arf and Rho family GTPases, thereby coupling receptor tyrosine kinase signals to endocytic trafficking and actin cytoskeleton reorganization. ARAP1 is activated downstream of EGFR stimulation and PI3K signaling, and it interacts with adaptor proteins such as CIN85 and APPL1 to localize to endosomal membranes. Through its GAP activities, ARAP1 regulates the activities of RhoA, Cdc42, and Rac1, which in turn control actin polymerization and cellular motility. It also modulates EGFR endocytosis and recycling via interactions with Rab5 and phosphoinositides. Thus, ARAP1 serves as a molecular switch that coordinates receptor internalization, signal termination, and cytoskeletal remodeling in response to external cues.
In the A-549 adenocarcinoma context, ARAP1 knockout disrupts the regulation of EGFR trafficking and Rho GTPase-dependent cytoskeletal dynamics, leading to altered EGFR surface levels, aberrant Akt activation, and changes in cell migration and invasion. Since aberrant EGFR signaling and Rho GTPase activity are hallmarks of NSCLC progression and drug resistance, this polyclonal knockout model provides a physiologically relevant system to dissect ARAP1’s contributions to these processes. It is valuable for comparative studies with wild-type A-549 cells to identify ARAP1-dependent phenotypes in lung adenocarcinoma.
Researchers can utilize this polyclonal knockout population for diverse functional studies, including Western blotting and RT-qPCR to confirm ARAP1 disruption and monitor EGFR, phospho-Akt, and Rho pathway components. Immunofluorescence microscopy enables visualization of EGFR localization and actin organization, while Transwell assays assess migration and invasion. Flow cytometry quantifies EGFR surface levels, and co-immunoprecipitation examines ARAP1 interactions with CIN85 and APPL1. Drug sensitivity assays can evaluate the role of ARAP1 in therapeutic response. These applications make the model valuable for studying endocytic trafficking, signal transduction, and cancer cell behavior. For additional information, contact Ascent Research.
